# US 2025/0367253 A1 · Gip/glp1 agonist compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367253 A1
- Document ID: US20250367253A1
- Status: Published application
- Kind: A1
- Application number: 19/276,978
- Filed: 2025-07-22
- Published: 2025-12-04
- Earliest claimed: 2018-06-22
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Vincent John CORVARI; Christopher Sears MINIE; Dinesh Shyamdeo MISHRA; Ken Kangyi QIAN
- Web page: https://patentgrep.com/patent/US20250367253A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 38/26: Glucagons
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61M 5/20: Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 takes precedence)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A pharmaceutical composition comprising:
(a) tirzepatide, or a pharmaceutically acceptable salt thereof; and
(b) from about 6.2 mg/mL to about 9.5 mg/mL of NaCl, wherein the pharmaceutical composition has a pH of from about 6.5 to about 7.5 and the composition is free of preservative.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition comprises from about 7.0 mg/mL to about 9.0 mg/mL of NaCl.

### Claim 46 (depends on 45)

The pharmaceutical composition of claim 45, wherein the composition comprises about 8.2 mg/mL of NaCl.

### Claim 47 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition has a pH of from about 6.7 to about 7.3.

### Claim 48 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition comprises from about 5 mg/mL to about 30 mg/mL of tirzepatide, or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the composition comprises 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, or 30 mg/mL of tirzepatide, or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition is administered using an automatic injection apparatus.

### Claim 51 (depends on 44)

The pharmaceutical composition of claim 44, wherein the preservative is selected from the group consisting of metacresol and phenol.
